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Abstract Chronicinterstitialcystitis(IC),mostlyaffecting
middle-aged women, is a very rare manifestation of primary
Sjo ¨gren’s syndrome (pSS). Hereby, we report a 42-year-old
woman with pSS, presenting with dysuria, urinary fre-
quency, and suprapubic pain. She was diagnosed to have
chronic IC, based upon the cystoscopic biopsy ﬁnding of
chronic inﬂammation in the bladder wall. Systemic corti-
costeroid and azathioprine treatments together with local
intravesical therapies were not effective. Therefore, cyclo-
sporine(CSA)therapywasinitiated.InitiallowdoseofCSA
(1.5 mg/kg/d)improvedthesymptomsofthepatient,withno
requirement for dose increment. After 4 months of therapy,
control cystoscopic biopsy showed that bladder inﬂamma-
tionregressedandICimproved.Thiscasesuggeststhateven
low doses of CSA may be beneﬁcial for treating chronic IC
associated with pSS syndrome.
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Introduction
Primer Sjo ¨gren syndrome (pSS) is a chronic autoimmune
disease characterized by lymphocytic inﬁltration of the
salivary and lacrimal glands, and associated with various
autoantibodies, especially anti-Ro/SS-A and anti-La/SS-B
antibodies [1]. During the progression of pSS, nearly 40%
of the pSS patients also develop extraglandular manifes-
tations including pulmonary, hepatic, renal involvement.
Other than these extraglandular system/organ involve-
ments, chronic interstitial cystitis (IC) may also occur,
albeit rarely, in the course of the pSS, as recently observed
in several patients [2–4].
IC, also known as painful bladder syndrome, is a chronic
inﬂammatory disease of the bladder occurring mainly in
women (F/M:9/1), primarily during middle ages. IC is
largely deﬁned by symptoms of urinary urgency and fre-
quency associated with pelvic pain that varies with bladder
ﬁlling. Data including the course and the treatment of IC
associated with pSS are scarce. Hereby, we report a case of
IC complicating pSS, resistant to systemic corticosteroid
and azathioprine (AZA) treatments, and local intravesical
treatment, but responsive to even low doses of cyclosporine
(CSA) treatment.
Case
A 42-year-old Turkish woman was admitted to Ege Uni-
versity Rheumatology outpatient clinic on March 2000 with
the complaints of dry eyes, dry mouth, and Raynaud’s phe-
nomenon. Autoantibody proﬁle showed positive homoge-
nous ANA with a 1/640 titer and positive anti-Ro. Minor
salivary gland biopsy revealed Chisholm stage III. These
ﬁndings led to the diagnosis of pSS based upon the latest
European Classiﬁcation criteria [5] and we commenced
hydroxychloroquine 200 mg/d. Since 2006, the patient had
also suffered from dysuria, urgency, pollakiuria, and supra-
pubic and perineal pain. Kidney function tests were normal,
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symptoms, we performed cystoscopic examination and
biopsy in September 2006. The biopsy specimens revealed
diffuseepithelialandsubepithelialedemawithinﬁltrationby
lymphocytes and mast cells. Based on these ﬁndings, the
diagnosis of IC was made. Infectious etiology was excluded
by appropriate tests and autoimmune etiology in the context
ofpSSwasconsidered.Sincethecasewasconsideredtohave
extraglandular involvement of pSS, initial treatment con-
sisting of moderatedose methylprednisone (24 mg/day)and
AZA (2 mg/kg/day) was commenced on December 2006.
The methylprednisone dose was tapered gradually to
4 mg/day in 3 months, and AZA treatment continued in the
samedose.However,thistreatmentremainedineffectiveand
intravesical lidocaine and amitriptyline therapies were also
added. Unfortunately, addition of local treatments was
helpful only for a short period of time, and after 2 months,
symptoms recurred. The Interstitial Cystitis Symptom Index
(ICSI) was calculated as 20 points [6]. Therefore, cysto-
scopic examination and urinary bladder biopsy were repe-
ated on April 2009. The histological ﬁndings included
ulceration of epithelial cells, urothelial separation and sub-
epithelial hemorrhagia, edematous and hemorrhagic lamina
propria and prominent submucosal inﬂammatory cell inﬁl-
tration, mostly mast cells. Mast cell tryptase activity impli-
cated substantially increased mast cells (Fig. 1a, b). In
addition to clinical inefﬁcacy, these histological ﬁndings
also supported that AZA therapy was not successful.
Therefore, we decided to change the immunosuppressive
agent.SinceitwaspreviouslyshownthatlowdoseCSAwas
asafeandeffectivechoice,wepreferredtouseCSA(2,7,8).
The patient was 74 kg in weight and CSA 1.5 mg/kg/day
(100 mg/day) was started. Methylprednisolone dose was
increased to 24 mg/day, and the dose was gradually
decreased to 4 mg/day in 2 months. In the fourth month of
therapy, the patient’s lower urinary tract symptoms dra-
maticallyimprovedandtheISCIscoredecreasedto2points.
Cystoscopy and bladder biopsy were repeated for the third
time to assess whether the treatment was also effective from
histologicalpointofview.Itwasfoundthathemorrhagiaand
edema in the lamina propria were replaced by early ﬁbrosis
and there was only slight inﬂammatory inﬁltration mostly
consisting of mononuclear cells (Fig. 1c, d).
The patient is currently in the ﬁrst year of CSA treat-
ment plus low dose methylprednisone. Her complaints are
completely regressed and she is being followed up in
clinical remission.
Discussion
Hereby, we presented a pSS case complicated with chronic
IC, resistant to combination of medium dose steroids, AZA
and local intravesical treatments, but successfully treated
with low dose of CSA combined with medium to low dose
steroids. This patient is also notable with having three
cystoscopic biopsies with available histopathologic bladder
ﬁndings, representing a spectrum ranging from the initial
active phase, to post-AZA treatment period (Fig. 1a, b),
and ﬁnally to remission phase induced by CSA treatment
(Fig. 1c, d). In other words, the beneﬁcial effects of CSA
were shown not only clinically and by ICSI score, but also
by histological examination.
During the course of pSS, interstitial cystitis may
develop, albeit rarely [2, 3]. In 1993, Van de Merwe et al.
[3] studied 10 patients with IC, 2 of whom were diagnosed
as having pSS. Haarala et al. [4] reported the frequency of
lower urinary tract problems in patients with pSS. They
found that the patients with pSS have signiﬁcantly more
urinary complaints than age- and sex-matched controls
(61% vs. 34%, respectively).
Treatment experience is extremely limited in IC com-
plicating pSS. Although traditional disease-modifying
agents including hydroxychloroquine and AZA are fre-
quently used in the treatment of extraglandular involve-
ment of pSS, data regarding their efﬁcacy in general and
especially in suppressing the symptoms of IC are not
available. However, CSA in combination with corticoste-
roids has been found to be more effective, even in cases of
dryness associated with pSS [2]. So, it may be worthwhile
to consider CSA treatment in patients with pSS with
extraglandular organ involvement. Supporting this view,
CSA was favorably used in the treatment of patients with
chronic idiopathic IC, as reported in more recent studies.
Shibata et al. [2] reported a case with pSS, who presented
with bilateral hydroureteronephrosis, acute renal failure
and IC, and successfully treated with CSA and steroids.
CSA was given at a dose 100 mg daily in that case. Sim-
ilarly, the dose of CSA used by Sairenen et al. [7, 8] for the
maintenance treatment of patients with chronic idiopathic
IC was 1–1.5 mg/kg once daily. Based on these reports, we
also preferred to switch AZA to low dose CSA, rather than
switching to high dose CSA or cyclophosphamide (CYP).
During the course of other chronic autoimmune diseases
including systemic lupus erythematosus (SLE), rheumatoid
arthritis and Hashimoto’s thyroiditis, interstitial cystitis
may also rarely occur. CYP and high dose corticosteroid
treatment may be useful at regressing bladder involvement
in SLE (lupus cystitis), but not every patient responds
satisfactorily to this treatment [9–11].
Intravesical treatment of chronic idiopathic IC generally
provides only short-term beneﬁts. Therefore, additional
systemic therapy is generally required. Recent publications
indicate that best oral systemic treatment options for idi-
opathic IC include pentosan polysulfate sodium, amitrip-
tyline, hydroxyzine, and CSA [8, 12].
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increase in the number of the mast cells, as in our case.
Activated mast cells release various vasoactive, noci-
ceptive, and proinﬂammatory molecules that may cause
immune cell inﬁltration and sensory nerve sensitization.
The mechanism of action of CSA may involve the
inhibition of stem cell factor mediated mast cell activa-
tion [13].
In conclusion, the presence of lower urinary tract
symptoms in patients with pSS should raise the possibility
of associated IC. If the diagnosis of IC is conﬁrmed and the
differential diagnosis points out an autoimmune origin in
the context of pSS, low dose CSA may be a good choice
for treatment.
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